- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020 ; volume:6 ; number:1 ; day:27 ; month:9 ; year:2011 ; pages:1-10 ; date:12.2011
Orphanet journal of rare diseases ; 6, Heft 1 (27.9.2011), 1-10, 12.2011
- Urheber
-
Schey, Carina
- Beteiligte Personen und Organisationen
-
Milanova, Tsveta
Hutchings, Adam
SpringerLink (Online service)
- DOI
-
10.1186/1750-1172-6-62
- URN
-
urn:nbn:de:1111-2016050120235
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schey, Carina
- Milanova, Tsveta
- Hutchings, Adam
- SpringerLink (Online service)
Ähnliche Objekte (12)
Estimating the budget impact of orphan drugs in Sweden and France 2013–2020
Public spending on orphan medicines: a review of the literature
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Impact of orphan drugs on Latvian budget
Application of four pricing models for orphan medicines: a case study for lumasiran
Establishing medical plausibility in the context of orphan medicines designation in the European Union
Use of biomarkers in the context of orphan medicines designation in the European Union
Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries
The Orphan
Orphan Island
Estimating New Zealand's Structural Budget Balance
10th European Conference on Rare Diseases & Orphan Products (ECRD 2020)
Estimating the budget impact of orphan drugs in Sweden and France 2013–2020
Public spending on orphan medicines: a review of the literature
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Impact of orphan drugs on Latvian budget
Application of four pricing models for orphan medicines: a case study for lumasiran
Establishing medical plausibility in the context of orphan medicines designation in the European Union
Use of biomarkers in the context of orphan medicines designation in the European Union
Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries
The Orphan
Orphan Island
Estimating New Zealand's Structural Budget Balance
10th European Conference on Rare Diseases & Orphan Products (ECRD 2020)
Estimating the budget impact of orphan drugs in Sweden and France 2013–2020
Public spending on orphan medicines: a review of the literature
Estimating the clinical cost of drug development for orphan versus non-orphan drugs
Impact of orphan drugs on Latvian budget
Application of four pricing models for orphan medicines: a case study for lumasiran
Establishing medical plausibility in the context of orphan medicines designation in the European Union
Use of biomarkers in the context of orphan medicines designation in the European Union
Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries
The Orphan
Orphan Island
Estimating New Zealand's Structural Budget Balance